ArticleAsian Pacific journal of cancer prevention : APJCP2025
In Silico Analysis Reveals MDM2 as a Potential Target of Ursolic Acid for Overcoming Tamoxifen Resistance in Breast Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveUrsolic acid (UA) has been proven to inhibit various cancer signaling pathways; however, the involvement of UA in overcoming tamoxifen resistance remains unclear and needs further investigation. This study aims to discover the potential gene targets and explore how ursolic acid interacts with those genes to restore sensitivity to tamoxifen.
methodsAnalyzing gene expression data from GeneCards and Swisstargetprediction for UA related genes, and the Gene Expression Omnibus (GEO) for tamoxifen resistance genes. DEGs were analyzed for functional annotation and molecular pathways using DAVID v6.8, continued with constructing a protein-protein interaction (PPI) network to highlight crucial genes associated with tamoxifen resistance using STRING-DB and Cytoscape. Genetic alteration analysis using cBioportal for target validation and consideration. Molecular docking was done using Autodock4 and PyMoL for visualisation.
resultsThe KEGG pathway and PPI network suggest that MDM2, STAT3, TGFB1, and MAPK1 were indicated as potential target genes of UA. Genetic alteration analysis further confirms that MDM2 has the highest alteration, which becomes potentially targeted by UA. Molecular docking analysis confirms that UA can target MDM2 by targeting the N-terminus site on 4HBM and 5ZXF structure. The binding energy of UA is -5.36 for 4HBM and -8.71 for 5ZXF, with all RMSD values below 2. This result shows that UA has a lower docking score than the native ligand for the 5ZXF structure. Additionally, MDM2 is mainly involved in the PI3K-Akt pathway, which plays a role in the chemotherapy resistance mechanism.
conclusionMDM2 has become a potential target for UA to reverse the tamoxifen resistance mechanism in breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.